TP53 and neoplasm: The in vivo observation that partial loss of MDM2 caused by a hypomorphic Mdm2 allele can still exert tumor suppression in mice without the premature aging phenotype linked to excess p53 activation provides additional rationale for the development of MDM2 RING inhibitors which may render proper therapeutic windows to inhibit the MDM2-p53 axis [114].